{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-121017","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2021-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.924084+00:00","generated_at":"2026-06-29T00:16:34.767250+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eloxx enters $50M at-the-market equity distribution agreement with SVB Leerink","bullets":["Up to $50M in common stock may be sold through SVB Leerink as sales agent under ATM program.","SVB Leerink receives 3% commission on gross sales proceeds; company provides customary indemnification.","Shares sold pursuant to existing S-3 shelf registration and prospectus supplement dated Sept 30, 2021.","Company is not obligated to sell any shares; agreement can be terminated by either party at any time."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-121017","json":"https://secwatch.observer/filing/0001104659-21-121017.json","markdown":"https://secwatch.observer/filing/0001104659-21-121017.md","text":"https://secwatch.observer/filing/0001104659-21-121017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921121017/0001104659-21-121017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921121017/tm2128746d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T00:16:34.767250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}